Timing of key drug could save lives in rare immune storm

NCT ID NCT07497438

First seen Apr 04, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This study tests whether giving the drug etoposide early, when organ failure first starts, works better than waiting in people with severe hemophagocytic lymphohistiocytosis (HLH) in the intensive care unit. HLH is a rare condition where the immune system overreacts, causing dangerous inflammation and organ damage. The trial will compare two approaches in 176 adults to see which reduces organ failure and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Intensive Care Unit - Avicenne Hospital, Assistance Publique des Hôpitaux de Paris

    Bobigny, 93000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.